Search results
Showing 6286 to 6300 of 8787 results
Sophie Cooper, senior scientific adviser at NICE, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
More than 20,000 people benefitting from innovative migraine pills recommended by NICE
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
NICE publishes first quality standard to improve care for people with rare diseases
Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.
How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.
Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.
How NICE guidance is accelerating access to innovative migraine treatments
Home News Podcasts How NICE guidance is accelerating access to innovative migraine treatments Podcasts 26 February 2026 Listen About this
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Weight management: BMI calculation in preceding 5 years (IND167)
This indicator has been withdrawn following discussions with the National Screening Committee.
This guidance has been updated and replaced by NICE indicator 277.